Sofosbuvir/velpatasvir/voxilaprevir

Drug Profile

Sofosbuvir/velpatasvir/voxilaprevir

Alternative Names: GS 9857/sofosbuvir/velpatasvir; GS-5816/GS-9857/sofosbuvir; GS-7977/GS-5816/GS-9857; GS-9857/GS-5816/sofosbuvir; GS-9857/SOF/VEL; GS-9857/VEL/SOF; GS-9857/velpatasvir/sofosbuvir; SOF/GS-9857/VEL; SOF/VEL/GS-9857; SOF/VEL/VOX; Sofosbuvir/GS-5816/GS-9857; Sofosbuvir/GS-9857/velpatasvir; Sofosbuvir/velpatasvir/GS-9857; VEL/GS-9857/SOF; VEL/SOF/GS-9857; Velpatasvir/GS-9857/sofosbuvir; Velpatasvir/sofosbuvir/GS-9857; Vosevi

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 17 Aug 2017 Registered for Hepatitis C (Treatment-experienced) in Canada (PO)
  • 17 Aug 2017 The US FDA and Canada approved label for Sofosbuvir/velpatasvir/voxilaprevir carries a black box warning
  • 28 Jul 2017 Registered for Hepatitis C in European Union, Norway, Liechtenstein, Iceland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top